Bria-IMT + checkpoint inhibitor: Phase I/II survival results compared to benchmark trials in metastatic breast cancer.
Saranya Chumsri(Jacksonville College), Carmen Calfa(University of Miami), Marcela Salgado(Ark Therapeutic (United States)), Kendrith M. Rowland(Columbus Community Clinical Oncology Program), John George Knecht, Chaitali Nangia(University of California, Irvine Medical Center), William L. Williams(University of Ottawa), Blaise Bayer(Ark Therapeutic (United States)), Giuseppe Del Priore(Supélec), Charles L. Wiseman(Ark Therapeutic (United States)), Ralph V. Boccia(Center for Cancer and Blood Disorders), Minal Barve(Mary Crowley Cancer Research Center)
Cited by 1
Related Papers
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study
|Journal of Clinical Oncology|2005|541
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|456
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425